Drugs / SLV337
last change Dec 2010 re-read 2 minutes ago

SLV337

Developed for
type 2 diabetes mellitus
Investigated by
Abbott Products · Quintiles, Inc. · Solvay Pharmaceuticals

Trials 3 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01176201 Jul → Oct 2010 Abbott Products Completed No outcome recorded
Phase 1 NCT00924430 Jun → Jul 2009 type 2 diabetes mellitus Solvay Pharmaceuticals Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00924534 Dec 2009 → Dec 2010 type 2 diabetes mellitus Abbott Products Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as SLV337 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01176201
2

NCT00924534

NCT00924430

Route Oral “after a single dose of an oral suspension of 14C-SLV337” NCT01176201